Shield Therapeutics plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SHIEF research report →
Price Chart
About the company
Shield Therapeutics plc operates as a specialized pharmaceutical firm, dedicated to developing and bringing to market advanced clinical therapies that address significant unfulfilled medical requirements. Its flagship product, Accrufer/Feraccru, offers an innovative, non-salt-based oral treatment specifically for adults suffering from iron deficiency, irrespective of whether anemia is present. Furthermore, the company is advancing PT20, a pioneering iron-based phosphate binder that has successfully concluded its pivotal Phase II trials for managing hyperphosphatemia in individuals with chronic kidney disease.
- CEO
- Anders Lundstrom
- IPO
- 2019
- Employees
- 61
- HQ
- Gateshead, GH, GB
Get TickerSpark's AI analysis on SHIEF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $91.55M
- P/E
- -7.09
- Fwd P/E
- 16.49
- PEG
- -0.07
- P/S
- 1.27
- P/B
- -4.34
- EV/EBITDA
- -28.23
- Div Yield
- 0.00%
- Gross Margin
- 50.58%
- Op Margin
- -7.02%
- Net Margin
- -17.76%
- ROE
- 64.57%
- ROIC
- -51.87%
Latest fiscal year · YoY change
- Revenue
- $50.81M+26.2%
- Gross Profit
- $22.41M+20.0%
- Op Income
- $-10,310,311
- Net Income
- $-18,047,645+46.9%
- EPS
- $-0.02+45.3%
- OCF Growth
- -30.3%
- FCF Growth
- +3.8%
- 52W High
- $0.17
- 52W Low
- $0.05
- 50D MA
- $0.08
- 200D MA
- $0.11
- Beta
- 1.72
- RSI (14)
- 79
- Avg Volume
- 33.45K
No earnings-call transcripts are available for SHIEF yet.
- Free Float
- 38.2%
- Shares Outstanding
- 1.07B
- Float Shares
- 408.88M
Our SHIEF coverage
Recent articles, reports, and earnings notes.
No research on SHIEF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SHIEF report →Shield Therapeutics plc (SHIEF) Discusses Strategic Acquisition of Full U.S. Commercial Control of ACCRUFeR Transcript
seekingalpha.com · Sep 1
Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris
proactiveinvestors.co.uk · Aug 28
Shield Therapeutics jumps 11% as losses narrow and profitability target held
proactiveinvestors.co.uk · Aug 20
Shield Therapeutics plc (SHIEF) Q2 2026 Sales/Trading Call Transcript
seekingalpha.com · Jul 30
Shield Therapeutics shares slip after interims, small-cap pharma says its still 'on-track'
proactiveinvestors.co.uk · Jul 30
Shield Therapeutics plc (SHIEF) Q1 2026 Sales/Trading Call Transcript
seekingalpha.com · May 5
Shield Therapeutics drops as CFO exits and Medicaid concerns weigh
proactiveinvestors.com · May 1
Shield Therapeutics drops as CFO exits and Medicaid concerns weigh
proactiveinvestors.co.uk · May 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.